Form 4: Black Diamond Therapeutics Director Acquires and Disposes of Shares

Director Shannon Campbell acquired and disposed of Black Diamond Therapeutics (BDTX) common stock on September 20, 2024, according to a Form 4 filing.

Summary

• On September 20, 2024, Shannon Campbell, a director of Black Diamond Therapeutics, Inc. (BDTX), engaged in transactions involving the company's common stock.
• Campbell acquired 2,354 shares of common stock at a price of $4.78 per share.
• Campbell also disposed of 4,365 shares.
• Following these transactions, Campbell directly owns 4,365 shares of Black Diamond Therapeutics.
• The shares were issued in lieu of cash compensation for annual services as a non-employee director, according to the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy.
• The price reported is based on the closing market price of BDTX common stock on September 19, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company director.
• The issuance of shares in lieu of cash compensation could slightly dilute existing shareholders.

Key Dates